pl
en
Country
pl
Language
en
Janssen.tv Janssen.tv MENU

Case study: own experience in the three-drug therapy using telaprevir in hepatitis C patients.

Speciality: Infectious diseases
Language : Polski
Broadcast type : Open broadcast
Duration : 00:57:39
Date: June 10, 2014

The live feed includes three cases of difficult-to-treat patients who are subject to a three drug therapy

Lecturers

Dorota Dybowska, MD
Internal medicine, Infectious diseases Dorota Dybowska, MD Poland Nicolaus Copernicus University; Ludwik Rydygier Collegium Medicum in Bydgoszcz, Faculty of Medicine, Department of Infectious Diseases and Hepatology
Maciej Jabłkowski, MD, Ph.D
Internal medicine, Infectious diseases Maciej Jabłkowski, MD, Ph.D Poland Department of Infectious Diseases of the Medical University of Łódź
Ewa Janczewska, MD, Ph.D
Internal medicine, Infectious diseases Ewa Janczewska, MD, Ph.D Poland ID Clinic

Other in: Infectious diseases

HIV eradication possibilities
Infectious diseases HIV eradication possibilities Miłosz Parczewski, MD, Ph.D
PL
The future of HIV infection therapy
Infectious diseases The future of HIV infection therapy Miłosz Parczewski, MD, Ph.D
PL
Debate: Why shouldn't patients wait for a three-drug therapy?
Infectious diseases Debate: Why shouldn't patients wait for a three-drug therapy? Prof. Anna Boroń-Kaczmarska, MD, Ph.D
Jerzy Jaroszewicz, MD, Ph.D
Ewa Janczewska, MD, Ph.D
PL
Debate: Telaprevir - a practical approach to the therapy: anemia, rash, others. Part 3: Others
Infectious diseases Debate: Telaprevir - a practical approach to the therapy: anemia, rash, others. Part 3: Others Several lecturers
PL
Debate: Telaprevir - a practical approach to the therapy: anemia, rash, others. Part 2: Rash
Infectious diseases Debate: Telaprevir - a practical approach to the therapy: anemia, rash, others. Part 2: Rash Several lecturers
PL
Debate: Telaprevir - a practical approach to the therapy: anemia, rash, others. Part 1: Anemia
Infectious diseases Debate: Telaprevir - a practical approach to the therapy: anemia, rash, others. Part 1: Anemia Several lecturers
PL
Initial efficacy and safety assessment of telaprevir in combination with interferon and ribaviryn in a Polish cohort of patients with advanced liver fibrosis and cirrhosis
Infectious diseases Initial efficacy and safety assessment of telaprevir in combination with interferon and ribaviryn in a Polish cohort of patients with advanced liver fibrosis and cirrhosis Ewa Janczewska, MD, Ph.D
PL
Trial design of the impact of modified RBV doses on the efficacy of triple therapy with telaprevir in patients infected with 1 HCV genotype with advanced liver fibrosis with prior treatment failure
Infectious diseases Trial design of the impact of modified RBV doses on the efficacy of triple therapy with telaprevir in patients infected with 1 HCV genotype with advanced liver fibrosis with prior treatment failure Prof. Robert Flisiak, MD, Ph.D
PL
Telaprevir in Polish clinical practice
Infectious diseases Telaprevir in Polish clinical practice Hanna Berak, MD
PL
Telaprevir in Polish clinical practice
Infectious diseases Telaprevir in Polish clinical practice Beata Dobracka, MD
PL
Telaprevir in Polish clinical practice
Infectious diseases Telaprevir in Polish clinical practice Ewa Janczewska, MD, Ph.D
PL
Telaprevir in Polish clinical practice
Infectious diseases Telaprevir in Polish clinical practice Dorota Kozielewicz, MD
PL
Telaprevir in Polish clinical practice
Infectious diseases Telaprevir in Polish clinical practice Prof. Tadeusz W. Łapiński, MD, Ph.D
PL
Telaprevir in Polish clinical practice
Infectious diseases Telaprevir in Polish clinical practice Dorota Zarębska-Michaluk, MD, Ph.D
PL